Ipca Laboratories Ltd (IPCALAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Ipca Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Schedule of Conference Call
Intimation · 05 Nov 2026, 4:00 pm
Ipca Laboratories Schedules Q2FY27 Earnings Conference Call Ipca Laboratories Limited will host an earnings conference call for investors and analysts on 5th Nov'26 from 16:00 to 17:00 hrs IST, following the announcement of its Q2FY27 unaudited financial results on the same day. Managing Director A. K. Jain and Corporate Counsel & Company Secretary Harish Kamath will represent the management team to discuss financial performance and provide business updates. The call will be hosted by DAM Capital Advisors Ltd. Universal dial-in numbers include +91-22-6280 1384 and +91-22-7115 8285.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Ipca Laboratories Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 05 Nov 2026, 5:30 am
Ipca Laboratories Board Meeting Scheduled for 5th Nov'26 to Consider Q2 Results Ipca Laboratories Limited announced that its Board of Directors will meet on 5th Nov'26 to consider and approve standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities by insiders remains closed from 1st Oct'26 until 7th Nov'26, concluding 48 hours post the declaration of the financial results pursuant to SEBI Insider Trading regulations.
Transcript of Conference Call
Transcript · 17 Aug 2026, 5:29 pm
Ipca Labs Q1FY27: Revenue Guidance Raised, Margins Improve on Strong Growth Ipca Labs reported strong Q1FY27 results, with consolidated revenue up 21% YoY to INR 2,788 crores. Consolidated EBITDA margin improved significantly to 22.88% from 18.39% in Q1FY26, driven by operating leverage. Domestic formulations grew 13%, exports 34%, and APIs 30%. Citing strong performance, management raised full-year FY27 revenue growth guidance to 14-16% from 12-13% previously. FY27 consolidated EBITDA margin guidance was also revised upwards to ~23% from 22%. Capex is guided at INR 700-800 crores for the year.
Audiolink for Conference Call held on 14.08.2026
Audio / Video · 14 Aug 2026, 10:48 pm
Ipca Labs Provides Audio Link for Q1FY27 Earnings Conference Call Ipca Laboratories has released the audio link for its conference call held on 14th Aug'26. The call discussed the company's Q1FY27 earnings and provided a business update. The filing was made to the BSE (524494) and NSE (IPCALAB) exchanges in compliance with Regulation 30 of SEBI regulations.
76th AGM - Voting Results and Scrutinizer Report
Annual General Meeting · 14 Aug 2026, 4:32 pm
Proceedings of AGM
Annual General Meeting · 13 Aug 2026, 11:01 pm
Standalone and Consolidated Unaudited Financial Results for Q1FY27
Financial Result · 13 Aug 2026, 7:10 pm
Ipca Labs Q1 FY27: Strong Revenue Growth and Margin Expansion Boosts Profit Ipca Laboratories reported robust Q1 FY27 results, with consolidated revenue rising 21% YoY to ₹2,788.10 crores and net profit soaring 72% YoY to ₹401.89 crores. Growth was driven by a 34% YoY increase in exports to ₹935.39 crores and a 13% YoY rise in Indian formulations to ₹1,082.12 crores. Consolidated EBITDA margin expanded significantly to 22.88% from 18.39% in Q1 FY26. Standalone net profit also grew 42% YoY to ₹373.29 crores, with an EPS of ₹14.71, beating estimates.
Standalone and Consolidated Unaudited Financial Results for Q1FY27
Outcome · 13 Aug 2026, 7:03 pm
Ipca Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Crore) ■ Revenue: 2,788 (+20.8% YoY | +16.7% QoQ) ■ EBITDA: 670 (+60.8% YoY | +38.4% QoQ) ■ EBITDA Margin (%): 24.0 (+598 bps YoY | +375 bps QoQ) ■ PAT: 402 (+72.3% YoY | +34.4% QoQ) ■ EPS (INR): 15.8 (+72.4% YoY | +19.0% QoQ)
Conference Call to discuss Q1FY27 Results
Intimation · 14 Aug 2026, 3:30 pm
Ipca Laboratories Schedules Q1FY27 Earnings Call for 14th August 2026 Ipca Laboratories (BSE: 524494, NSE: IPCALAB) will host a conference call for investors and analysts on 14th Aug'26 at 15:30 IST. The call, hosted by Dam Capital Advisors, will discuss Q1FY27 earnings and business updates. This follows the scheduled announcement of its financial results on 13th Aug'26. Management representation will include Managing Director Mr. A K Jain and Corporate Counsel Mr. Harish Kamath.
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 13 Aug 2026, 5:30 am
Ipca Laboratories Board Meeting on 13th Aug'26 to Approve Q1 FY27 Results Ipca Laboratories has scheduled a Board of Directors meeting on 13th Aug'26 to approve standalone and consolidated unaudited financial results for the first quarter ending 30th Jun'26. The trading window for insiders will remain closed from 1st Jul'26 until 15th Aug'26, which is 48 hours after the results are declared. This action complies with SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
Intimation of web link to non-email cases
Others (Uncategorized) · 17 Jul 2026, 8:51 pm
Ipca Laboratories Schedules 76th Annual General Meeting for Aug'26 Ipca Laboratories will hold its 76th Annual General Meeting (AGM) via video conference on 13 Aug'26 at 3:30 p.m. IST. The company has dispatched the FY26 Annual Report link to shareholders whose email addresses were not registered as of the 10 Jul'26 cut-off date. This communication also serves as a reminder for physical security holders to update KYC details, including PAN and bank information, to ensure eligibility for dividends and other payments, which are now processed only electronically.
Record Date for Dividend
Dividend · 14 Jul 2026, 9:21 pm
Ipca Laboratories Sets Record Date for Dividend Ipca Laboratories has fixed Fri, 7th Aug'26 as the Record Date for determining dividend eligibility. The potential dividend of ₹6 per share (600%), subject to approval at the Annual General Meeting on 13th Aug'26, will be paid on or before 10th Sep'26. The company has opted for a record date instead of a book closure for this purpose.
76th Annual General Meeting of Ipca Laboratories Limited to be held on Thursday, 13th August, 2026
Annual General Meeting · 14 Jul 2026, 9:17 pm
Business Responsibility and Sustainability Reporting (BRSR)
Others (Uncategorized) · 14 Jul 2026, 4:17 pm
Ipca Laboratories FY26 Business Responsibility and Sustainability Report Highlights Ipca Laboratories released its Business Responsibility and Sustainability Report for FY25-26 on 14 Jul’26. Key environmental metrics show total energy consumption increased to 2,568,332 GJ from 2,432,387 GJ YoY, while water consumption slightly decreased to 979,005 kilolitres. Scope 1 and 2 GHG emissions totaled 302,144 tCO2e, down from 288,874 tCO2e. Exports contributed over 42% to standalone revenue. Employee turnover for permanent staff rose to 27.2% from 25.2% in FY25. Accounts payable days increased to 67 from 56 YoY.
Annual Report 2025-26
Others (Uncategorized) · 14 Jul 2026, 3:41 pm
Credit Rating
Others (Uncategorized) · 07 Jul 2026, 5:33 pm
Ipca Laboratories Credit Ratings Affirmed by India Ratings & Research On Jul 07, '26, India Ratings & Research affirmed Ipca Laboratories' credit ratings. The rating for its INR 500 million Commercial Paper was affirmed at 'IND A1+'. The rating for its Bank Loan Facilities was affirmed at 'IND AA+/Stable' for long-term and 'IND A1+' for short-term. The size of the bank loan facilities was notably reduced from INR 25,937.30 million to INR 22,481.10 million. The affirmation signals continued creditworthiness and stable financial standing for the company.
Outcome of Board Meeting
Others (Uncategorized) · 26 Jun 2026, 6:45 pm
Outcome of Board Meeting
Others (Uncategorized) · 26 Jun 2026, 6:39 pm
Press Release
Press Release · 12 Jun 2026, 10:56 pm
Ipca Labs In-Licenses Biologics Delivery Tech from BRL for Oncology & Inflammatory Drugs Ipca Laboratories announced on 12 Jun'26 a global licensing deal with Bhami's Research Laboratory (BRL). The agreement provides Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform. This technology will be used to develop and commercialize multiple monoclonal antibody products targeting oncology and inflammatory diseases worldwide. Under the deal terms, BRL will receive defined milestone fees for technology transfer and subsequent royalties on net sales after commercialization. Ipca will handle further R&D, clinical trials, and commercial manufacturing.
Transcript of Conference Call held on 1st June 2026
Transcript · 04 Jun 2026, 7:14 pm
Ipca Laboratories Q4FY26 Earnings Call Highlights and FY27 Guidance For Q4FY26, Ipca's domestic formulation business grew 12% to INR 853 crores. Consolidated EBITDA margin improved to 20.52% from 18.24% YoY. For FY26, consolidated revenue grew 8% to INR 9,646 crores, with EBITDA margin at 20.72% vs 19.94%. Management guided for 12-13% consolidated growth for FY27, with India business also growing 12-13%. Consolidated EBITDA margin is expected to improve to around 22-22.3%, despite an anticipated 10-12% rise in raw material costs, which management plans to offset through product mix changes and price hikes.
Audio Link of the Conference Call held on 01.06.2026
Audio / Video · 01 Jun 2026, 10:44 pm
Ipca Labs Provides Audio Link for Q4FY26 Earnings Conference Call Ipca Laboratories has released the audio link for its conference call held on 1st Jun'26 at 15:30 IST. The call was organized to discuss the company's Q4FY26 earnings results and provide a general business update to investors and analysts. The recording is available on the company's website under the shareholder information section. This provides access to management's commentary and the subsequent Q&A session, offering insights into the company's performance and outlook.
Revised Link for Q4FY26 Conference Call to be held today
Intimation · 01 Jun 2026, 3:30 pm
Ipca Labs Issues Revised Link for Q4FY26 Earnings Call Ipca Laboratories has issued a revised passcode link for its conference call to discuss Q4FY26 earnings and provide a business update. The call is scheduled for today, 1st Jun'26, at 15:30 hrs IST. The notice was filed with both the BSE (Scrip Code: 524494) and NSE (Scrip Code: IPCALAB), providing the updated access details for investors and analysts.
Recommendation of Dividend
Dividend · 29 May 2026, 7:33 pm
Ipca Labs Board Recommends Dividend and Reports Q4/FY26 Results Ipca Laboratories reported Q4 FY26 consolidated net profit of ₹299.07 crores, up 341% YoY, on revenue of ₹2,388.48 crores (+6% YoY). The Board recommended a dividend of ₹6 per share (600%) for FY26, with a record date of 7th Aug'26, subject to shareholder approval. For the full year, consolidated net profit rose 55% YoY to ₹1,141.12 crores. Additionally, the Board approved the re-appointment of Mr. Prashant Godha as Executive Director for a five-year term effective 16th Aug'26.